315 related articles for article (PubMed ID: 34812550)
21. SF3B1 mutant myelodysplastic syndrome: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
[TBL] [Abstract][Full Text] [Related]
22. Nonsense-Mediated RNA Decay Is a Unique Vulnerability of Cancer Cells Harboring
Cheruiyot A; Li S; Nonavinkere Srivatsan S; Ahmed T; Chen Y; Lemacon DS; Li Y; Yang Z; Wadugu BA; Warner WA; Pruett-Miller SM; Obeng EA; Link DC; He D; Xiao F; Wang X; Bailis JM; Walter MJ; You Z
Cancer Res; 2021 Sep; 81(17):4499-4513. PubMed ID: 34215620
[TBL] [Abstract][Full Text] [Related]
23. The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action.
Finci LI; Zhang X; Huang X; Zhou Q; Tsai J; Teng T; Agrawal A; Chan B; Irwin S; Karr C; Cook A; Zhu P; Reynolds D; Smith PG; Fekkes P; Buonamici S; Larsen NA
Genes Dev; 2018 Feb; 32(3-4):309-320. PubMed ID: 29491137
[TBL] [Abstract][Full Text] [Related]
24. Identification of a small molecule splicing inhibitor targeting UHM domains.
Kobayashi A; Clément MJ; Craveur P; El Hage K; Salone JM; Bollot G; Pastré D; Maucuer A
FEBS J; 2022 Feb; 289(3):682-698. PubMed ID: 34520118
[TBL] [Abstract][Full Text] [Related]
25. Targeting splicing factors for cancer therapy.
Bashari A; Siegfried Z; Karni R
RNA; 2023 Apr; 29(4):506-515. PubMed ID: 36697261
[TBL] [Abstract][Full Text] [Related]
26. Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1).
Chung FF; Tan PF; Raja VJ; Tan BS; Lim KH; Kam TS; Hii LW; Tan SH; See SJ; Tan YF; Wong LZ; Yam WK; Mai CW; Bradshaw TD; Leong CO
Sci Rep; 2017 Feb; 7():42504. PubMed ID: 28198434
[TBL] [Abstract][Full Text] [Related]
27. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
Makishima H; Visconte V; Sakaguchi H; Jankowska AM; Abu Kar S; Jerez A; Przychodzen B; Bupathi M; Guinta K; Afable MG; Sekeres MA; Padgett RA; Tiu RV; Maciejewski JP
Blood; 2012 Apr; 119(14):3203-10. PubMed ID: 22323480
[TBL] [Abstract][Full Text] [Related]
28. Spliceosomal factor mutations and mis-splicing in MDS.
Hershberger CE; Daniels NJ; Padgett RA
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101199. PubMed ID: 33038983
[TBL] [Abstract][Full Text] [Related]
29. Non-canonical functions of spliceosome components in cancer progression.
Ivanova OM; Anufrieva KS; Kazakova AN; Malyants IK; Shnaider PV; Lukina MM; Shender VO
Cell Death Dis; 2023 Feb; 14(2):77. PubMed ID: 36732501
[TBL] [Abstract][Full Text] [Related]
30. Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.
Jyotsana N; Heuser M
Expert Opin Ther Targets; 2018 Feb; 22(2):107-121. PubMed ID: 29235382
[TBL] [Abstract][Full Text] [Related]
31. SnapShot: Splicing Alterations in Cancer.
Rahman MA; Krainer AR; Abdel-Wahab O
Cell; 2020 Jan; 180(1):208-208.e1. PubMed ID: 31951519
[TBL] [Abstract][Full Text] [Related]
32. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome.
Mian SA; Smith AE; Kulasekararaj AG; Kizilors A; Mohamedali AM; Lea NC; Mitsopoulos K; Ford K; Nasser E; Seidl T; Mufti GJ
Haematologica; 2013 Jul; 98(7):1058-66. PubMed ID: 23300180
[TBL] [Abstract][Full Text] [Related]
33. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
Brierley CK; Steensma DP
Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment.
Lin JC
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29283381
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the aberrant splicing of MAP3K7 induced by cancer-associated SF3B1 mutation.
Li Z; Zhao B; Shi Y; Liang Y; Qian R; Wan Y
J Biochem; 2021 Sep; 170(1):69-77. PubMed ID: 33751071
[TBL] [Abstract][Full Text] [Related]
36. CRISPR editing of sftb-1/SF3B1 in Caenorhabditis elegans allows the identification of synthetic interactions with cancer-related mutations and the chemical inhibition of splicing.
Serrat X; Kukhtar D; Cornes E; Esteve-Codina A; Benlloch H; Cecere G; Cerón J
PLoS Genet; 2019 Oct; 15(10):e1008464. PubMed ID: 31634348
[TBL] [Abstract][Full Text] [Related]
37. Pan-cancer analysis identifies mutations in
Liu Z; Zhang J; Sun Y; Perea-Chamblee TE; Manley JL; Rabadan R
Proc Natl Acad Sci U S A; 2020 May; 117(19):10305-10312. PubMed ID: 32332164
[TBL] [Abstract][Full Text] [Related]
38. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.
Kesarwani AK; Ramirez O; Gupta AK; Yang X; Murthy T; Minella AC; Pillai MM
Oncogene; 2017 Feb; 36(8):1123-1133. PubMed ID: 27524419
[TBL] [Abstract][Full Text] [Related]
39. The spliceosome is a therapeutic vulnerability in MYC-driven cancer.
Hsu TY; Simon LM; Neill NJ; Marcotte R; Sayad A; Bland CS; Echeverria GV; Sun T; Kurley SJ; Tyagi S; Karlin KL; Dominguez-Vidaña R; Hartman JD; Renwick A; Scorsone K; Bernardi RJ; Skinner SO; Jain A; Orellana M; Lagisetti C; Golding I; Jung SY; Neilson JR; Zhang XH; Cooper TA; Webb TR; Neel BG; Shaw CA; Westbrook TF
Nature; 2015 Sep; 525(7569):384-8. PubMed ID: 26331541
[TBL] [Abstract][Full Text] [Related]
40. The U1 spliceosomal RNA is recurrently mutated in multiple cancers.
Shuai S; Suzuki H; Diaz-Navarro A; Nadeu F; Kumar SA; Gutierrez-Fernandez A; Delgado J; Pinyol M; López-Otín C; Puente XS; Taylor MD; Campo E; Stein LD
Nature; 2019 Oct; 574(7780):712-716. PubMed ID: 31597163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
